EBITDA: Income before interest, taxes, depreciation and amortization.
Esperion Therapeutics, Inc. (ESPR) had EBITDA of $7.94M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$82.39M |
|
$-12.72M |
|
$28.54M |
|
$53.84M |
|
$75.29M |
|
$7.09M |
|
$-19.82M |
|
$-12.72M |
|
$-12.72M |
|
$-12.72M |
|
$-12.72M |
|
$-12.72M |
|
$-12.72M |
|
$7.09M |
|
|
EBITDA |
$7.94M |
197.55M |
|
197.55M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$342.60M |
|
$0.20M |
|
$4.49M |
|
$347.08M |
|
$298.80M |
|
$243.45M |
|
$481.80M |
|
$780.59M |
|
$-433.51M |
|
$-433.56M |
|
$-433.51M |
|
200.16M |
|
| Cash Flow Statement Financials | |
$-54.05M |
|
-- |
|
$-4.65M |
|
$144.76M |
|
$86.06M |
|
$-58.70M |
|
$5.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.15 |
|
-- |
|
-- |
|
-1.28 |
|
-0.69 |
|
65.35% |
|
8.61% |
|
8.61% |
|
-- |
|
-15.45% |
|
-15.45% |
|
$-54.05M |
|
-- |
|
-- |
|
-- |
|
0.24 |
|
0.25 |
|
0.76 |
|
117.71 |
|
2.94% |
|
2.94% |
|
-3.67% |
|
6.70% |
|
$-2.17 |
|
$-0.27 |
|
$-0.27 |
|